213 related articles for article (PubMed ID: 22079605)
1. Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.
Prabhakaran S; Sweet A
Contraception; 2012 May; 85(5):453-7. PubMed ID: 22079605
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.
Cameron ST; Glasier A; Johnstone A
Contraception; 2012 May; 85(5):458-64. PubMed ID: 22079602
[TBL] [Abstract][Full Text] [Related]
3. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
Upadhyay UD; Zlidar VM; Foster DG
Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
[TBL] [Abstract][Full Text] [Related]
4. Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood.
Kohn JE; Simons HR; Della Badia L; Draper E; Morfesis J; Talmont E; Beasley A; McDonald M; Westhoff CL
Contraception; 2018 Mar; 97(3):198-204. PubMed ID: 29246818
[TBL] [Abstract][Full Text] [Related]
5. Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial.
Picardo C; Ferreri S
Contraception; 2010 Aug; 82(2):160-7. PubMed ID: 20654757
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
[TBL] [Abstract][Full Text] [Related]
7. Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial.
Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
Lancet Glob Health; 2018 May; 6(5):e568-e578. PubMed ID: 29526707
[TBL] [Abstract][Full Text] [Related]
8. The role of training in effective simulated self-injection of subcutaneous depot medroxyprogesterone acetate: observations from a usability study.
Kaplan I; Ross D; Hilton F; Morgenstern D; Wolter K
Contraception; 2016 Oct; 94(4):314-20. PubMed ID: 27241898
[TBL] [Abstract][Full Text] [Related]
9. Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women.
Williams RL; Hensel DJ; Fortenberry JD
Contraception; 2013 Sep; 88(3):401-7. PubMed ID: 23294549
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study.
Cover J; Ba M; Lim J; Drake JK; Daff BM
Contraception; 2017 Sep; 96(3):203-210. PubMed ID: 28673645
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.
Beasley A; White KO; Cremers S; Westhoff C
Contraception; 2014 May; 89(5):352-6. PubMed ID: 24656555
[TBL] [Abstract][Full Text] [Related]
12. Continuation of injectable contraception when self-injected vs. administered by a facility-based health worker: a nonrandomized, prospective cohort study in Uganda.
Cover J; Namagembe A; Tumusiime J; Nsangi D; Lim J; Nakiganda-Busiku D
Contraception; 2018 Nov; 98(5):383-388. PubMed ID: 29654751
[TBL] [Abstract][Full Text] [Related]
13. Administration of depot medroxyprogesterone acetate on the day of mifepristone for medical abortion: a pilot study.
Sonalkar S; McClusky J; Hou MY; Borgatta L
Contraception; 2015 Feb; 91(2):174-7. PubMed ID: 25481376
[TBL] [Abstract][Full Text] [Related]
14. Factors Affecting Continued Use of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC): A Secondary Analysis of a 1-Year Randomized Trial in Malawi.
Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Santo LD; Ngwira B
Glob Health Sci Pract; 2019 Mar; 7(1):54-65. PubMed ID: 30894394
[TBL] [Abstract][Full Text] [Related]
15. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
Polaneczky M; Guarnaccia M; Alon J; Wiley J
Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283
[TBL] [Abstract][Full Text] [Related]
16. Young Women's Experiences With Subcutaneous Depot Medroxyprogesterone Acetate: A Secondary Analysis of a One-Year Randomized Trial in Malawi.
Burke HM; Chen M; Packer C; Fuchs R; Ngwira B
J Adolesc Health; 2020 Nov; 67(5):700-707. PubMed ID: 32389457
[TBL] [Abstract][Full Text] [Related]
17. Women's satisfaction, use, storage and disposal of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) during a randomized trial.
Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
Contraception; 2018 Nov; 98(5):418-422. PubMed ID: 29758176
[TBL] [Abstract][Full Text] [Related]
18. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
19. The acceptability of self-administration of subcutaneous Depo-Provera.
Lakha F; Henderson C; Glasier A
Contraception; 2005 Jul; 72(1):14-8. PubMed ID: 15964286
[TBL] [Abstract][Full Text] [Related]
20. Immediate monthly combination contraception to facilitate initiation of the depot medroxyprogesterone acetate contraceptive injection.
Morroni C; Grams M; Tiezzi L; Westhoff C
Contraception; 2004 Jul; 70(1):19-23. PubMed ID: 15208048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]